Weight-Loss drug trial aims to curb drinking and heal livers

NCT ID NCT07046819

Summary

This study is testing whether a medication called tirzepatide, currently used for weight management, can help people who struggle with heavy alcohol use and the related liver damage it causes. About 120 adults with alcohol use disorder and a specific type of metabolic liver disease will receive weekly injections of either the real drug or a placebo for 12 weeks. Researchers will measure if the drug helps participants reduce their drinking, lose weight, and improve the health of their liver.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.